239 related articles for article (PubMed ID: 18508540)
1. Antisense DNA and RNA agents against picornaviruses.
Lim T; Yuan J; Zhang HM; Sall A; Liu Z; Su Y; Yang D
Front Biosci; 2008 May; 13():4707-25. PubMed ID: 18508540
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibitors of picornavirus replication.
De Palma AM; Vliegen I; De Clercq E; Neyts J
Med Res Rev; 2008 Nov; 28(6):823-84. PubMed ID: 18381747
[TBL] [Abstract][Full Text] [Related]
3. Antisense tumor therapy (a dream under construction).
Kopper L; Kovalszky I
In Vivo; 1994; 8(5):781-6. PubMed ID: 7727725
[TBL] [Abstract][Full Text] [Related]
4. Picornavirus inhibitors.
Carrasco L
Pharmacol Ther; 1994; 64(2):215-90. PubMed ID: 7533301
[TBL] [Abstract][Full Text] [Related]
5. Strand-specific silencing of a picornavirus by RNA interference: evidence for the superiority of plus-strand specific siRNAs.
Schubert S; Rothe D; Werk D; Grunert HP; Zeichhardt H; Erdmann VA; Kurreck J
Antiviral Res; 2007 Mar; 73(3):197-205. PubMed ID: 17112603
[TBL] [Abstract][Full Text] [Related]
6. [The application of antisense technology in ophthalmology].
Guo Y; Ge J
Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046
[TBL] [Abstract][Full Text] [Related]
7. RNA as a target for developing antivirals.
McKnight KL; Heinz BA
Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917
[TBL] [Abstract][Full Text] [Related]
8. Antisense technology for cancer therapy: does it make sense?
Carter G; Lemoine NR
Br J Cancer; 1993 May; 67(5):869-76. PubMed ID: 8494718
[No Abstract] [Full Text] [Related]
9. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
[TBL] [Abstract][Full Text] [Related]
10. Strategies to identify potential therapeutic target sites in RNA.
Lützelberger M; Kjems J
Handb Exp Pharmacol; 2006; (173):243-59. PubMed ID: 16594619
[TBL] [Abstract][Full Text] [Related]
11. RNAi: a novel antisense technology and its therapeutic potential.
Dallas A; Vlassov AV
Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
[TBL] [Abstract][Full Text] [Related]
12. Antiviral agents against picornaviruses.
Eggers HJ
Antiviral Res; 1985; Suppl 1():57-65. PubMed ID: 3002267
[No Abstract] [Full Text] [Related]
13. Antisense and sensibility.
Dove A
Nat Biotechnol; 2002 Feb; 20(2):121-4. PubMed ID: 11821852
[No Abstract] [Full Text] [Related]
14. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.
Wagner A; Bock CT; Fechner H; Kurreck J
Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598
[No Abstract] [Full Text] [Related]
15. DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes.
Fokina AA; Stetsenko DA; François JC
Expert Opin Biol Ther; 2015 May; 15(5):689-711. PubMed ID: 25772532
[TBL] [Abstract][Full Text] [Related]
16. Prospects for nucleic acid-based therapeutics against hepatitis C virus.
Lee CH; Kim JH; Lee SW
World J Gastroenterol; 2013 Dec; 19(47):8949-62. PubMed ID: 24379620
[TBL] [Abstract][Full Text] [Related]
17. Antisense technologies. Improvement through novel chemical modifications.
Kurreck J
Eur J Biochem; 2003 Apr; 270(8):1628-44. PubMed ID: 12694176
[TBL] [Abstract][Full Text] [Related]
18. [Pleconaril, a new aniviral drug with activity against picornavirus].
Reina J; Ballesteros F
Rev Esp Quimioter; 2000 Sep; 13(3):257-62. PubMed ID: 11086273
[No Abstract] [Full Text] [Related]
19. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
20. Nucleic acids-based therapeutics in the battle against pathogenic viruses.
Haasnoot J; Berkhout B
Handb Exp Pharmacol; 2009; 189(189):243-63. PubMed ID: 19048203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
